CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
stocks

ASX healthcare leader sees further cuts to fair value

Fiercer competition expected to squeeze margins.
stocks

Top stocks of the year: Which opportunities remain in 2026?

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,673.8010.700.12%
CAC 407,807.87162.01-2.03%
DAX 4022,839.56662.69-2.82%
Dow JONES (US)46,052.46172.69-0.37%
FTSE 10010,063.50241.79-2.35%
HKSE25,388.99111.59-0.44%
NASDAQ22,085.6266.80-0.30%
Nikkei 22553,372.531,866.87-3.38%
NZX 50 Index12,989.62325.98-2.45%
S&P 5006,606.3018.40-0.28%
S&P/ASX 2008,481.809.500.11%
SSE Composite Index4,003.033.52-0.09%

Market Movers